Huang David B, Sader Helio S, Rhomberg Paul R, Gaukel Eric, Borroto-Esoda Katyna
Lysovant Sciences, Inc., New York, NY, USA.
JMI Laboratories, North Liberty, IA, USA.
Diagn Microbiol Infect Dis. 2021 Nov;101(3):115471. doi: 10.1016/j.diagmicrobio.2021.115471. Epub 2021 Jun 26.
LSVT-1701 (previously known as SAL200), is a novel, recombinantly-produced, bacteriophage-encoded lysin that specifically targets staphylococci via cell wall enzymatic hydrolysis. In vitro activities of LSVT-1701 and comparators were tested against 415 Staphylococcus aureus and coagulase-negative staphylococci (CoNS) clinical isolates expressing various resistance phenotypes. The isolates were collected worldwide from 2002 to 2019 and tested for in vitro susceptibility using broth microdilution methodology performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) interpretations were based on CLSI and EUCAST criteria. MIC for all S. aureus, methicillin-susceptible S. aureus, methicillin-resistant S. aureus, and CoNS, were 2, 2, 2 and 2 µg/ml, respectively. LSVT-1701's activity was not adversely affected by resistance to antimicrobial comparators against this worldwide collection of S. aureus and CoNS clinical isolates. The results of this study support further clinical development of LSVT-1701 to treat staphylococcal infections, including those caused by multidrug resistance isolates.
LSVT - 1701（先前称为SAL200）是一种新型的、重组生产的、噬菌体编码的溶素，它通过细胞壁酶解作用特异性地靶向葡萄球菌。对LSVT - 1701及对照品针对415株表达各种耐药表型的金黄色葡萄球菌和凝固酶阴性葡萄球菌（CoNS）临床分离株进行了体外活性测试。这些分离株于2002年至2019年在全球范围内收集，并根据临床和实验室标准协会（CLSI）指南采用肉汤微量稀释法进行体外药敏试验。最低抑菌浓度（MIC）的判读依据CLSI和欧洲药敏试验委员会（EUCAST）标准。所有金黄色葡萄球菌、甲氧西林敏感金黄色葡萄球菌、甲氧西林耐药金黄色葡萄球菌和CoNS的MIC分别为2、2、2和2μg/ml。针对全球范围内收集的金黄色葡萄球菌和CoNS临床分离株，LSVT - 1701的活性不受对抗菌对照品耐药性的不利影响。本研究结果支持LSVT - 1701进一步开展治疗葡萄球菌感染的临床研究，包括由多重耐药分离株引起的感染。
